Insmed Future Growth
Future criteria checks 2/6
Insmed is forecast to grow earnings and revenue by 39.6% and 34.6% per annum respectively. EPS is expected to grow by 42.1% per annum. Return on equity is forecast to be -609.1% in 3 years.
Key information
39.6%
Earnings growth rate
42.1%
EPS growth rate
| Biotechs earnings growth | 0% |
| Revenue growth rate | 34.6% |
| Future return on equity | -609.1% |
| Analyst coverage | Good |
| Last updated | 12 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 825 | -426 | -312 | -201 | 12 |
| 12/31/2025 | 503 | -672 | -620 | -563 | 15 |
| 12/31/2024 | 357 | -722 | -655 | -611 | 15 |
| 12/31/2023 | 305 | -750 | -550 | -536 | N/A |
| 9/30/2023 | 281 | -724 | -524 | -509 | N/A |
| 6/30/2023 | 269 | -696 | -476 | -462 | N/A |
| 3/31/2023 | 257 | -547 | -453 | -442 | N/A |
| 12/31/2022 | 245 | -482 | -410 | -400 | N/A |
| 9/30/2022 | 242 | -434 | -388 | -381 | N/A |
| 6/30/2022 | 221 | -416 | -374 | -367 | N/A |
| 3/31/2022 | 201 | -438 | -348 | -340 | N/A |
| 12/31/2021 | 188 | -435 | -371 | -363 | N/A |
| 9/30/2021 | 174 | -424 | -354 | -346 | N/A |
| 6/30/2021 | 171 | -375 | -336 | -329 | N/A |
| 3/31/2021 | 168 | -319 | -295 | -290 | N/A |
| 12/31/2020 | 164 | -294 | -226 | -219 | N/A |
| 9/30/2020 | 169 | -245 | -215 | -197 | N/A |
| 6/30/2020 | 164 | -242 | -223 | -191 | N/A |
| 3/31/2020 | 151 | -247 | -276 | -235 | N/A |
| 12/31/2019 | 136 | -254 | -293 | -251 | N/A |
| 9/30/2019 | 101 | -293 | -310 | -276 | N/A |
| 6/30/2019 | 62 | -320 | -311 | -290 | N/A |
| 3/31/2019 | 32 | -330 | -278 | -264 | N/A |
| 12/31/2018 | 10 | -324 | -273 | -258 | N/A |
| 9/30/2018 | N/A | -298 | -248 | -236 | N/A |
| 6/30/2018 | N/A | -256 | -219 | -209 | N/A |
| 3/31/2018 | N/A | -224 | -198 | -190 | N/A |
| 12/31/2017 | N/A | -193 | -163 | -160 | N/A |
| 9/30/2017 | N/A | -196 | N/A | -169 | N/A |
| 6/30/2017 | N/A | -188 | N/A | -162 | N/A |
| 3/31/2017 | N/A | -180 | N/A | -154 | N/A |
| 12/31/2016 | N/A | -176 | N/A | -147 | N/A |
| 9/30/2016 | N/A | -139 | N/A | -116 | N/A |
| 6/30/2016 | N/A | -132 | N/A | -109 | N/A |
| 3/31/2016 | N/A | -124 | N/A | -105 | N/A |
| 12/31/2015 | N/A | -118 | N/A | -101 | N/A |
| 9/30/2015 | N/A | -105 | N/A | -86 | N/A |
| 6/30/2015 | N/A | -98 | N/A | -83 | N/A |
| 3/31/2015 | N/A | -92 | N/A | -77 | N/A |
| 12/31/2014 | N/A | -79 | N/A | -64 | N/A |
| 9/30/2014 | N/A | -78 | N/A | -66 | N/A |
| 6/30/2014 | N/A | -71 | N/A | -61 | N/A |
| 3/31/2014 | N/A | -57 | N/A | -48 | N/A |
| 12/31/2013 | N/A | -56 | N/A | -47 | N/A |
| 9/30/2013 | N/A | -55 | N/A | -42 | N/A |
| 6/30/2013 | N/A | -47 | N/A | -34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INSM * is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INSM * is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INSM * is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INSM *'s revenue (34.6% per year) is forecast to grow faster than the MX market (6.8% per year).
High Growth Revenue: INSM *'s revenue (34.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INSM * is forecast to be unprofitable in 3 years.